Stem cell committee urged to slow down
By Terri Somers,
San Diego Union-Tribune
| 01. 07. 2005
Ethics rules, transparency discussed at 2nd meeting
The committee that will dole out $3 billion in state grants for stem cell research heard yesterday from critics and some of its own members who said the group should slow down in its race to get money to scientists.
As the committee met for the second time, one of the overriding messages from the public and some of the committee members was to start by establishing standards for complicated and weighty issues such as how to reimburse taxpayers for their investment.
"No one wants results to come back faster than I do," said committee member Joan Samuelson, a former lawyer who has Parkinson's disease. "But some of these questions and issues are complicated. Some of the answers may take awhile."
The stem cell initiative that voters approved in November was set up to sidestep the slow crawl of bureaucracy and quickly get money to scientists looking for cures to diseases such as Parkinson's and Lou Gehrig's.
The committee's goal is to write the first check by the end of May, said Robert...
Related Articles
Image courtesy National Human Genome Research Institute
The U.S. Food and Drug Administration (FDA) is supposed to encourage effective medical advances while also ensuring that patients and research subjects are protected. This dual mandate demands tricky judgment calls that are made more difficult by outside pressures of several kinds, political, judicial, and especially commercial. This April story at Bloomberg examines one deeply troubling pattern of regulatory capture:
Americans Are Paying Billions to Take Drugs That Don’t Work
Companies are increasingly...
By Katie LaGrone, WPTV | 06.28.2024
Image by National Cancer Institute from Unsplash
TAMPA, Fla. — A Tampa jury recently found the now-defunct Lung Institute in Tampa guilty of engaging in “deceptive or unfair practices” while it offered customers “valueless” stem cell therapy to treat incurable...
By Peter Aldhous, Scientific American | 07.02.2024
In June a notice posted on the website of the journal Nature set a new scientific record. It withdrew what is now the most highly cited research paper ever to be retracted.
The study, published in 2002 by Catherine Verfaillie...
By Robert F. Service, Science | 07.04.2024
Image by Ed Uthman from Flickr
Last year, the U.S. Food and Drug Administration (FDA) approved two gene therapy procedures that can treat and, in some cases essentially cure sickle cell disease, a genetic blood disorder that causes pain and...